Hadassah Treats First COVID-19 Patient with New Concentrated Passive Vaccine
Hadassah Medical Center has treated its first COVID-19 patient with a new “passive vaccine” that the hospital developed in conjunction with Israeli biopharmaceutical firm Kamada. According to Hadassah’s head Zeev Rotstein, “the patient reacted positively.”
He said: “She started to improve hemodynamically… We have our fingers crossed for the successful treatment of this patient.”
Though he could not share details about the patient, he described her as a young woman suffering from several underlying medical conditions. She has been hospitalized for weeks and is intubated. He said other treatments have not shown any results.
The antibody (immunoglobulin or IgG) concentrate was developed using plasma that Hadassah harvested from recovered corona patients: those who had the disease and now test negative for the virus. (JPost / VFI News)
They will pick up serpents with their hands; and if they drink any deadly poison, it will not hurt them; they will lay their hands on the sick, and they will recover. —Mark 16:18
“God, we ask that you bring complete healing to this patient and that the promise of this and other treatments spells a quick recovery to those most at risk during this pandemic.”